The thesis

McKesson Corporation operates in the healthcare distribution layer with a 7.7% revenue growth rate. The company's low gross margin of 3.6% and net margin of 1.1% indicate a high-volume, low-margin business. Despite this, the analyst consensus rating is BUY, and the Decifer score is 47, indicating medium conviction. The current setup is interesting due to the contrast between the company's thin margins and its steady revenue growth.

Why now

The recent ISM manufacturing PMI slip in September and the slight increase in the USA Unemployment Rate to 4.2% may signal a broader economic shift that could impact healthcare demand. McKesson's steady revenue growth of 7.7% makes it a compelling watch in this context.

What to watch

The next quarter's revenue growth rate and any changes to the analyst consensus rating will be key indicators of McKesson's continued growth trajectory. Additionally, any developments in drug pricing policy will be crucial in assessing the company's risk profile.

Key risks

Drug pricing policy changes and trial failures are recurring shocks that could impact McKesson's business. A significant decline in revenue growth or an increase in competition could also invalidate the thesis.

Theme exposure